Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors

Background Our aim is to develop replication-competent viral vectors for mucosal delivery, which express HIV-Env immunogens that closely mimic the trimeric glycoprotein spike found on HIV particles. We have developed attenuated recombinant CDV (rCDV) expressing SIVmac239-Env and shown that this vector can be used safely to elicit Env-specific immune responses in ferrets and non-human primates through intranasal administration.